Clinical trials: LSD
Addiction;Drug(S);LSD, Neuroprotective
Neuroprotective Effect of (Nano PSO), in Patients Who Used to Consume Psychoactive Substances
Addiction problems to psychoactive substances are becoming more frequent, which implies a serious health problem, with social, family and work repercussions.
- Trial name
- NCT06550167
- Testing
- Nano-PSO, Pomegranate seed oil (omega-5)
- Where
- Mexico
- Volunteers
- 80 people
- Sponsor
- Distribuidora Biolife SA de CV
Lysosomal Storage Disorders, Sandhoff Disease
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PLX-200 in Pediatric Patients (Master Protocol)
The purpose of this study is to evaluate the safety, tolerability and clinical activity of PLX-200 in pediatric patients with lysosomal storage disorders.
- Conditions
- Lysosomal Storage Disorders, Sandhoff Disease, Krabbe Disease, CLN2
- Trial name
- NCT07740512
- Testing
- PLX-200
- Volunteers
- 24 people
- Sponsor
- Polaryx Therapeutics, Inc.
Liver Cirrhosis
Long-term Efficacy and Safety of LSD Versus TIPS for Cirrhotic Portal Hypertension Bleeding and Hypersplenism
This study aims to compare two treatments for cirrhotic portal hypertension with acute esophagogastric variceal bleeding and hypersplenism: laparoscopic splenectomy and azygoportal disconnection (LSD) and transjugular…
- Trial name
- LSD、TIPS (NCT07490405)
- Testing
- LSD, TIPS
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Northern Jiangsu People's Hospital
Fabry Disease
A Phase 1 Study To Evaluate the Safety of Migalastat Hydrochloride Given Intravenously to Healthy Volunteers
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of IV migalastat HCl alone and to determine absolute bioavailability for oral migalastat HCl as compared to IV administered migalastat HCl in…
- Trial name
- NCT02082327
- Testing
- IV migalastat HCl, oral migalastat HCl
- Where
- Netherlands
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Amicus Therapeutics
Healthy
Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects
The main objective of this study is to determine whether administration of ketanserin (40 mg), olanzapine (10 mg), and lorazepam (2 mg) after administration of LSD (150 µg) attenuates and shortens the subjective LSD response (any…
- Trial name
- LBL (NCT05964647)
- Testing
- LSD (150 µg) + ketanserin (40 mg), LSD (150 µg) + olanzapine (10 mg), LSD (150 µg) + lorazepam (2 mg)
- Where
- Switzerland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Lysosomal Storage Disorders, Gaucher Disease
Investigating Lysosomal Storage Diseases in Minority Groups
Although lysosomal storage disorders, such as Fabry disease, Gaucher disease, and Pompe disease, represent serious challenges in the healthcare system, no study has yet investigated the prevalence of these diseases in the US.
- Conditions
- Lysosomal Storage Disorders, Gaucher Disease, Fabry Disease, Pompe Disease
- Trial name
- NCT02120235
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- O & O Alpan LLC
Healthy
Effect of Ketanserin After LSD Administration
LSD (lysergic acid diethylamide) is a serotonergic (5-HT) hallucinogen widely used for recreational and/or ethnomedical purposes.
- Trial name
- L-Ket (NCT04558294)
- Testing
- Lysergic Acid Diethylamide, Ketanserin
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
LSD Reaction
LSD-Perceptual-Choice-Study
The aim of the study is to characterize the effects of low doses of LSD (d-lysergic acid diethylamide) on behavioral and neural indicators of feedback and feedforward signaling in perceptual decision-making.
- Trial name
- LUCY (NCT05976698)
- Testing
- LSD 10 μg, LSD 20 μg
- Where
- Switzerland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Major Depressive Disorder
LSD Therapy for Persons Suffering From Major Depression
Background: Major Depressive Disorder is one of the most prevalent mental illnesses, leading to substantial personal distress and economical consequences. Pharmacological Treatment is limited and relapse is frequent.
- Trial name
- LAD (NCT03866252)
- Testing
- LSD
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- University Hospital, Basel, Switzerland
Spondyloarthritis, Ankylosing Spondylitis
Effect of a Low Starch Diet in Patients With Ankylosing Spondylitis
The aim of this study is to explore the effect of a low starch diet (reduction of at least 40%) in the gut bacteria modulation, especially Klebsiella pneumoniae, and its relation to disease activity, functional impairment and…
- Trial name
- NCT04386538
- Testing
- Low Starch Diet (LSD), General healthy eating
- Where
- Portugal
- Volunteers
- 150 people
- Sponsor
- Universidade do Porto
ADHD, Attention Deficit Disorder
Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial
This study measures the safety and efficacy of repeated low dose MM120 as treatment for ADHD in adults: a multi-center, randomized, double-blind, placebo-controlled
- Trial name
- NCT05200936
- Testing
- MM120
- Where
- 2 sites in Netherlands, Switzerland
- Volunteers
- 53 people
- Sponsor
- Definium Therapeutics US, Inc.
Healthy
Neuronal Correlates of Altered States of Consciousness
The aim of the present study is to assess the neuronal correlates of alterations in waking consciousness pharmacologically induced by a 5-hydroxytryptamine (HT)2A receptor agonist in healthy subjects using functional magnetic…
- Trial name
- 5HT2A-fMRI (NCT02308969)
- Testing
- LSD
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
MPS IV A, Mucopolysaccharidosis IVA
A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
This multicenter, open-label extension study is designed to assess long-term efficacy and safety of 2.0 milligrams (mg)/kilogram(kg)/week of BMN 110 in patients diagnosed with Mucopolysaccharidosis IVA (MPS IVA).
- Conditions
- MPS IV A, Mucopolysaccharidosis IVA, Morquio A Syndrome
- Trial name
- NCT01242111
- Testing
- BMN 110
- Where
- 4 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- BioMarin Pharmaceutical
Healthy
LSD Base and LSD Tartrate Bioequivalence and Bioavailability in Healthy Subjects
Lysergic acid diethylamide (LSD) is used as recreational substance and as a research substance to study the mind. Recreationally, LSD is typically used in the form of "blotters" containing LSD tartrate.
- Trial name
- LSD-Bio (NCT04865653)
- Testing
- Lysergic Acid Diethylamide Base oral drinking solution, Lysergic Acid Diethylamide Base solid orodispersible film, Lysergic Acid Diethylamide Tartrate oral drinking solution
- Where
- Switzerland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Healthy Volunteers
A Double-blind, Placebo-controlled Study to Evaluate Very Low Dose LSD in Healthy Volunteers Aged 55-75 Years
This study was a Phase 1, double-blind, placebo-controlled, randomised study of very low dose LSD. Healthy volunteers aged 55 to 75 years with no use of LSD in the past 5 years were screened within 28 days of randomization.
- Trial name
- NCT04421105
- Testing
- Lysergic acid diethylamide (LSD) 5µg, Lysergic acid diethylamide (LSD) 10µg, Lysergic acid diethylamide (LSD)20 µg
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Eleusis Therapeutics
Healthy
Comparative Acute Effects of LSD, Psilocybin and Mescaline
LSD, psilocybin and mescaline are widely used for recreational and ethnomedical purposes. All three substances are thought to induce prototypical psychedelic effects primarily via stimulation of the 5-HT2A receptor.
- Trial name
- LPM (NCT04227756)
- Testing
- LSD, Psilocybin, Mescaline
- Where
- Switzerland
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Healthy
A Dose-Ranging Study of 50 µg to 100 µg LSD in Healthy Volunteers
This study with low-dose LSD comprised 2 substudies in healthy subjects. Subjects who met all inclusion and no exclusion criteria provided written informed consent.
- Trial name
- NCT05674669
- Testing
- Lysergic Acid Diethylamide (LSD) 50µg, Lysergic Acid Diethylamide (LSD) 75µg, Lysergic Acid Diethylamide (LSD) 100µg
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eleusis Therapeutics
Sodium Lactate, Intracranial Hypertension
Sodium Lactate and Brain Relaxation (LSD)
Resection surgery of brain tumors by craniotomy requires efficient brain relaxation intraoperatively in order to avoid injuries caused by the brain retractors (such as ischemic-reperfusion and cerebral oedema).
- Conditions
- Sodium Lactate, Intracranial Hypertension, Brain Relaxation
- Trial name
- LSD (NCT04488874)
- Testing
- Sodium Lactate, Mannitol 20% Infusion
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Mucopolysaccharidosis IVA, Morquio A Syndrome
Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome
The primary objective of this study was to evaluate the safety of a 2.0 mg/kg/week and a 4.0 mg/kg/week of BMN 110 in patients with Morquio A syndrome for up to 196 weeks.
- Conditions
- Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
- Trial name
- NCT01609062
- Testing
- BMN 110
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 25 people
- Sponsor
- BioMarin Pharmaceutical
Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD
The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training
The study investigates two groups of participants of the SÄPT therapist's training starting in October 2022. The overall objective is to investigate the risks and benefits of personal experience (PE) with substance-induced…
- Trial name
- TherPsySE (NCT05570708)
- Testing
- MDMA, LSD, psilocybin
- Where
- Switzerland
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Felix Mueller